Capricor Therapeutics Announces Third Quarter Results
Capricor Therapeutics (NASDAQ: CAPR), a company focused on innovative cell and exosome-based therapies for rare diseases, has announced it will unveil its financial results for the third quarter, ending September 30, in November. Following the release of its financial report, the management will conduct a conference call and webcast to discuss the outcomes and provide updates on the company’s initiatives. This presentation is set for 4:30 p.m. ET on the specified date.
What to Expect from the Conference Call
During the conference call, listeners can expect detailed insights regarding the company’s financial performance during the quarter. Management will highlight key achievements, clinical progress, and future plans related to its primary product candidates, including Deramiocel, a cellular therapy aimed at addressing Duchenne muscular dystrophy (DMD). Stakeholders are encouraged to participate in the call, which will be accessible for all interested parties.
Conference Call Details
The conference call can be accessed toll-free at 1-800-717-1738 or internationally at 1-646-307-1865. Participants will be greeted by an operator to assist them with the call. This is a valuable opportunity for investors and analysts to gather more detailed information and ask pertinent questions regarding Capricor’s strategy moving forward.
About Deramiocel
Capricor’s lead product candidate, Deramiocel, is an innovative cell therapy developed for the treatment of DMD. It has garnered attention due to its potent immunomodulatory and anti-fibrotic properties, which are crucial for preserving muscle function in patients suffering from this debilitating condition. With promising results from clinical trials, Capricor is dedicated to ensuring that these transformative therapies reach those in need.
Recent Corporate Developments
Recently, Capricor has been active in expanding its partnerships to enhance the reach and efficacy of its products. The company has entered a collaboration with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of Deramiocel in the U.S. and Japan, pending necessary regulatory approvals. This agreement is a significant step for Capricor, facilitating further advancements in the therapeutic landscape for rare diseases.
Innovative Technologies at Capricor
In addition to Deramiocel, Capricor is also leveraging its proprietary StealthX™ platform to advance exosome technology. This platform is instrumental in developing targeted therapies that can potentially treat a variety of diseases through the delivery of therapeutic agents, including oligonucleotides and proteins. Capricor's commitment to research and development is unwavering, as the company seeks to redefine treatment options for patients globally.
Commitment to Patients
At Capricor, the patient remains at the heart of all initiatives. The company strives to transform the treatment landscape through innovative solutions and holistic care approaches. Their ongoing research and clinical trials are critical in unlocking new potentials that could provide hope and relief to patients with rare diseases.
Frequently Asked Questions
What are Capricor Therapeutics' main products?
Capricor focuses on advanced cell and exosome-based therapies, with Deramiocel being its flagship product aimed at treating Duchenne muscular dystrophy.
When will the financial results for Q3 be released?
The financial results for the third quarter will be released after market close on November 10.
How can I participate in the conference call?
You can join the conference call by calling 1-800-717-1738 for toll-free access or 1-646-307-1865 for international callers.
What is the StealthX™ platform?
StealthX™ is Capricor's proprietary technology used for developing targeted therapies, enhancing the delivery of various therapeutic agents.
Who can I contact for more information?
For inquiries, reach out to Raquel Cona with KCSA Strategic Communications at rcona@kcsa.com or call 212.896.1204.
